Unlikely to cause harm — often a labeling or packaging issue.
Failed Impurities/Degradation Specifications: An out-of-specification (OOS) result was observed during release testing of one lot for a related substance, i.e. Beta-lumicolchicine.
| Distributed by / for | Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534 |
| NDC | 16714-0039-01 |
| Full product label | Colchicine Tablets, USP 0.6 mg, Rx Only, a) 30 tablets per bottle, NDC 16714-0039-01, b) 100 tablets per bottle, NDC 16714-0039-02, Manufactured for: NorthStar Rx LLC., Memphis, TN 38141, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, c) 100 tablets per bottle, NDC 70710-1351-01, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. |
| Recalling firm | Zydus Pharmaceuticals (USA) Inc |
| Distribution | AZ, OH, MS. |
| Quantity | 21,936/30 count bottles and 33,096/100 count bottles |
| Recall initiated | 2023-02-24 |
| Report date | 2023-03-22 |
| Recall completed | 2025-07-01 |
| Recall number | D-0467-2023 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Pennington NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗